Nuvectis Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVCT research report →
Range $33 – $40
Price Chart
About the company
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer.
- CEO
- Ron Bentsur
- IPO
- 2022
- Employees
- 19
- HQ
- Fort Lee, NJ, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a longer-term recovery regime, trading well above its 200-day average of 15.18 after a deep 52-week range from 5.77 to 29.28. That keeps the multi-month trend constructive, though the share price is still below the prior high and has not fully reclaimed the upper end of the range.
Street sentiment is constructive, with a Buy consensus and a $37.33 average target versus a recent close near $20.24. Recent actions have leaned positive, including a new Overweight call and multiple target raises into the $33 to $40 range, which supports a favorable longer-term setup.
The earnings profile is still uneven: NVCT has beaten just 1 of the last 8 quarters, and the most recent print missed by 363.6%. Next-year EPS is still expected to improve from -2.00 to -1.695, so shareholders should watch for tighter loss control and any sign the clinical story is translating into better operating leverage.
Insider activity skews positive, with 5 buys and no sells. The only discretionary purchases were by the CEO and a 10% owner, while the rest were awards and vesting-related grants that are less informative. That mix suggests alignment at the top, with real buying concentrated in senior leadership.
Profitability remains deeply negative, with ROE at -66.98% and ROA at -36.93%. Cash burn is still meaningful, with -$16.01 million in operating cash flow and -$16.01 million in free cash flow for 2025, but the company held $31.63 million in cash and equivalents.
As a clinical-stage oncology biotech, NVCT is valued on pipeline execution rather than current earnings power. The setup favors a premium multiple versus cash-burning peers if development progress continues, but the current -15.45 P/E and negative cash flow keep valuation tied to clinical milestones.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $666.80M
- P/E
- -10.26
- Fwd P/E
- 24.70
- PEG
- 0.24
- P/S
- 0.00
- P/B
- 4.51
- EV/EBITDA
- -10.02
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -119.87%
- ROIC
- -41.16%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-27,574,000
- Net Income
- $-26,442,000-39.2%
- EPS
- $-1.32-18.9%
- OCF Growth
- -30.7%
- FCF Growth
- -30.7%
- 52W High
- $29.28
- 52W Low
- $5.77
- 50D MA
- $20.21
- 200D MA
- $15.46
- Beta
- -0.24
- RSI (14)
- 47
- Avg Volume
- 206.37K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Nuvectis said the third quarter was transformative, with two China-licensed assets, a strengthened cash position, and multiple near-term regulatory and clinical catalysts.· November 4, 2026
- Closed a licensing deal with Haisco that added NXP-100 and NXP-200, shifting Nuvectis into a late-stage development story.
- Ended the quarter with approximately $140 million in cash after a $150 million follow-on offering and about $37 million sold through the ATM.
- NXP-100 won first approval in China for treatment-naive PNH, and a second China application for previously treated PNH is under review.
- Management said FDA discussions on the U.S. path for NXP-100 are active and constructive, with an update expected by year end.
- NXP-200 showed updated Phase 1b activity in gliomas at ESMO, including complete responses, and a U.S. IND filing is targeted by year end.
Nuvectis reported a net loss of $30.1 million for the quarter; excluding the upfront license payment, the one-time NXP-900 milestone, and noncash stock-based compensation, adjusted net loss was $5.8 million. The company ended the quarter with approximately $140 million in cash and said that cash should fund operations into the second half of 2029. Management also noted approximately $150 million in gross proceeds from a follow-on offering and about $37 million placed through the ATM facility in the third quarter. Looking ahead, the company expects an update on the U.S. regulatory path for NXP-100 by year end, a U.S. IND filing for NXP-200 by year end, and an approval in China for previously treated PNH patients in the first quarter of 2027.
Ron Bentsur framed the quarter as transformational, saying the Haisco licensing deal changed Nuvectis into a late-stage development company with two assets that have best-in-class potential. He emphasized that NXP-100 already has one China approval in PNH, that FDA interactions are ongoing, and that the company is preparing for multiple possible U.S. regulatory paths. His tone was highly confident and promotional, especially around NXP-100's once-daily dosing and NXP-200's emerging CNS profile.
No separate CFO remarks were provided; Ron Bentsur delivered the financial update. He cited a $30.1 million net loss, or $5.8 million adjusted net loss excluding the upfront license payment, one-time NXP-900 milestone, and stock-based compensation. He also highlighted the financing actions completed in the quarter, including the $150 million follow-on offering, approximately $37 million raised through the ATM, and the resulting approximately $140 million cash balance, which he said supports runway into the second half of 2029.
Most of the Q&A focused on the FDA's expectations for NXP-100 in U.S. PNH. Management said the FDA has asked detailed questions about how the China studies compare with U.S. standards and the Fabhalta program, and that the company believes it has answered those concerns, but it still expects the FDA may require one or two clinical studies. Questions also covered study design possibilities, site selection, and whether the work could involve placebo, active control, or switch studies; management said it is preparing for several options and has already started building site relationships. On NXP-200, management said it plans to pursue a U.S. IND and likely breakthrough designation, with more China data expected in the next few months and additional solid-tumor activity as a key factor.
Management said NXP-100 already has strong China Phase 3 data, an approval in treatment-naive PNH, and a second PNH filing under review, with a possible first-quarter 2027 approval for previously treated patients. They also pointed to a long cash runway, active FDA engagement, and multiple upcoming catalysts across PNH, IgA nephropathy, and NXP-200. For NXP-200, they highlighted complete responses in glioma and a broader solid-tumor signal that could support a best-in-class profile.
The biggest risk discussed was regulatory uncertainty in the U.S. for NXP-100: management said the FDA could require no studies, one study, or two studies, and they currently expect some kind of study to be required. NXP-200 still needs additional data from China and a U.S. IND before any U.S. clinical path begins, so the program remains early outside China despite encouraging signals. The company is also juggling multiple INDs and development plans as a small team, which management acknowledged is a meaningful execution challenge.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 64.8%
- Shares Outstanding
- 34.39M
- Float Shares
- 22.30M
of shares held by institutions
93 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Soleus Capital Management, L.P. | 1.71M | ▲ 710.66K |
| Tang Capital Management LLC | 1.58M | ▲ 27.97K |
| Braidwell LP | 1.57M | ▲ 1.57M |
| Blackrock, Inc. | 1.31M | ▲ 305.69K |
| Vanguard Capital Management LLC | 907.27K | ▲ 34.79K |
| Vanguard Group Inc | 845.50K | ▲ 146.79K |
| Geode Capital Management, LLC | 503.37K | ▲ 71.09K |
| Parkman Healthcare Partners LLC | 425.35K | ▲ 425.35K |
| State Street Corp | 369.00K | ▲ 120.80K |
| Occam Crest Management LP | 357.15K | 0 |
| Sphera Funds Management Ltd. | 323.43K | ▼ 59.52K |
| Schonfeld Strategic Advisors LLC | 260.30K | ▲ 248.54K |
Held by 114 ETFs
Biggest fund positions in NVCT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 3, 26 | Carson Michael J. | other | 30,000 |
| Jun 30, 26 | Mosseri Marlio Charles | buy | 50,000 |
| Jun 30, 26 | BENTSUR RON | buy | 12,500 |
| Jun 11, 26 | Hoberman Kenneth | other | 35,000 |
| Jun 11, 26 | Oliviero James F III | other | 35,000 |
| Jun 11, 26 | Sanchez Juan | other | 35,000 |
| Jun 11, 26 | Kaplan Matthew L. | other | 35,000 |
| Jan 6, 26 | Shemesh Shay | other | 150,000 |
| Jan 6, 26 | BENTSUR RON | other | 150,000 |
| Jan 6, 26 | Poradosu Enrique | other | 150,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NVCT coverage
Recent articles, reports, and earnings notes.
Want a deeper read on NVCT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Nuvectis Pharma Q3 Earnings Call Highlights
marketbeat.com · Nov 4
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
globenewswire.com · Nov 4
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
globenewswire.com · Nov 2
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
globenewswire.com · Oct 26
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up – What’s Next?
defenseworld.net · Oct 12
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
globenewswire.com · Oct 9
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25 According to Brokerages
defenseworld.net · Sep 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 15, 2026 · Live quote · Not investment advice
